Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Factors Associated with Fatal COVID-19 Outcomes among People Living with HIV: A Cohort Study

Author(s): Elena Drobyshevskaya, Aleksey Lebedev*, Alexander Pronin and Marina Bobkova

Volume 21, Issue 6, 2023

Published on: 30 November, 2023

Page: [367 - 377] Pages: 11

DOI: 10.2174/011570162X277788231128111517

Price: $65

conference banner
Abstract

Background: People living with HIV (PLHIV) are at increased risk of COVID-19 death. However, information about whether factors related to the HIV-infection influence the COVID-19 outcome still remains conflicting.

Objective: Here, we evaluate the risk factors for fatal COVID-19 in a cohort of PLHIV from the Moscow region, aged >18 years and diagnosed with COVID-19 between March 2020 and December 2021.

Methods: Demographic, clinical and laboratory data were compared between different COVID-19 outcomes. To analyze the risk factors associated with COVID-19 death, we employed the logistic regression method. A total of 566 PLHIV were included in the analysis.

Results: The majority of individuals, 338 (59.7%), were male; 194 (34.3%) were on antiretroviral therapy; 296 (52.3%) had a comorbidity; 174 (30.7%) of patients had drug and/or alcohol dependence; 160 (33.1%) patients had CD4 counts <200 cells/μl; 253 (51.9%) had undetectable viral load. Our analysis revealed that PLHIV >55 years old (OR, 12.88 [95% CI, 2.32-71.62]), patients with a viral load of more than 1000 copies/ml (OR, 2.45 [95%CI, 1.01-5.98]) and with CD4 counts <200 cell/μl (OR, 2.54 [95%CI, 1.02-6.28]), as well as with a history of cachexia (OR, 3.62 [95%CI, 1.26-10.39]) and pneumocystis pneumonia (OR, 2.47 [95%CI, 1.03-5.92]), and drug/alcohol dependence (OR, 2.70 [95%CI, 1.36-5.39]) were significantly more likely to die from COVID-19.

Conclusion: These data show that people with advanced HIV-1 infection have an increased risk of fatal COVID-19 outcomes and that there is a need to improve this population’s access to health services and, hence, increase their survival rates.

« Previous Next »
Graphical Abstract

[1]
WHO Coronavirus disease (COVID-19) dashboard. 2022. Available from: https://covid19.who.int/ (Accessed on: 2022 Dec 22).
[2]
Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg 2020; 78: 185-93.
[http://dx.doi.org/10.1016/j.ijsu.2020.04.018] [PMID: 32305533]
[3]
Kanyanda S, Markhof Y, Wollburg P, Zezza A. Acceptance of COVID-19 vaccines in sub-Saharan Africa: Evidence from six national phone surveys. BMJ Open 2021; 11(12): e055159.
[http://dx.doi.org/10.1136/bmjopen-2021-055159] [PMID: 34911723]
[4]
Liu Y, Han J, Li X, et al. COVID-19 Vaccination in People Living with HIV (PLWH) in China: A cross sectional study of vaccine hesitancy, safety, and immunogenicity. Vaccines 2021; 9(12): 1458.
[http://dx.doi.org/10.3390/vaccines9121458] [PMID: 34960204]
[5]
Suthar AB, Wang J, Seffren V, Wiegand RE, Griffing S, Zell E. Public health impact of covid-19 vaccines in the US: Observational study. BMJ 2022; 377: e069317.
[http://dx.doi.org/10.1136/bmj-2021-069317] [PMID: 35477670]
[6]
Ngo VM, Zimmermann KF, Nguyen PV, Huynh TLD, Nguyen HH. How education and GDP drive the COVID-19 vaccination campaign. Arch Public Health 2022; 80(1): 171.
[http://dx.doi.org/10.1186/s13690-022-00924-0] [PMID: 35850775]
[7]
Yi S, Choe YJ, Lim DS, et al. Impact of national Covid-19 vaccination Campaign, South Korea. Vaccine 2022; 40(26): 3670-5.
[http://dx.doi.org/10.1016/j.vaccine.2022.05.002] [PMID: 35570077]
[8]
Jones M, Khader K, Branch-Elliman W. Estimated impact of the US COVID-19 vaccination campaign-getting to 94% of deaths prevented. JAMA Netw Open 2022; 5(7): e2220391.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.20391] [PMID: 35793090]
[9]
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[10]
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020; 11: 1441.
[http://dx.doi.org/10.3389/fimmu.2020.01441] [PMID: 32612615]
[11]
Hussain M, Khurram Syed S, Fatima M, et al. Acute respiratory distress syndrome and COVID-19: A literature review. J Inflamm Res 2021; 14: 7225-42.
[http://dx.doi.org/10.2147/JIR.S334043] [PMID: 34992415]
[12]
Al Mutair A, Alhumaid S, Layqah L, et al. Clinical outcomes and severity of acute respiratory distress syndrome in 1154 COVID-19 patients: An experience multicenter retrospective cohort study. COVID 2022; 2(8): 1102-15.
[http://dx.doi.org/10.3390/covid2080081]
[13]
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health 2019. Available from: https://www.covid19treatmentguidelines.nih.gov/ (Accessed on: Dec 22, 2022).
[14]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[15]
Song J, Park DW, Cha J, et al. Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: A nationwide retrospective cohort study. Sci Rep 2021; 11(1): 10066.
[http://dx.doi.org/10.1038/s41598-021-89548-y] [PMID: 33980912]
[16]
Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. Aging Male 2020; 23(5): 1416-24.
[http://dx.doi.org/10.1080/13685538.2020.1774748] [PMID: 32508193]
[17]
Munblit D, Nekliudov NA, Bugaeva P, et al. Stop COVID Cohort: An observational study of 3480 patients admitted to the Sechenov University Hospital network in Moscow City for suspected Coronavirus Disease 2019 (COVID-19) infection. Clin Infect Dis 2021; 73(1): 1-11.
[http://dx.doi.org/10.1093/cid/ciaa1535] [PMID: 33035307]
[18]
Borobia A, Carcas A, Arnalich F, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med 2020; 9(6): 1733.
[http://dx.doi.org/10.3390/jcm9061733] [PMID: 32512688]
[19]
Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2(8): 1069-76.
[http://dx.doi.org/10.1007/s42399-020-00363-4] [PMID: 32838147]
[20]
Cho SI, Yoon S, Lee HJ. Impact of comorbidity burden on mortality in patients with COVID-19 using the Korean health insurance database. Sci Rep 2021; 11(1): 6375.
[http://dx.doi.org/10.1038/s41598-021-85813-2] [PMID: 33737679]
[21]
Virot E, Duclos A, Adelaide L, et al. Autoimmune diseases and HIV infection. Medicine 2017; 96(4): e5769.
[http://dx.doi.org/10.1097/MD.0000000000005769] [PMID: 28121924]
[22]
Maciel RA, Klück HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study. Int J Infect Dis 2018; 70: 30-5.
[http://dx.doi.org/10.1016/j.ijid.2018.02.009] [PMID: 29476902]
[23]
Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open 2020; 3(6): e207954.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.7954] [PMID: 32539152]
[24]
Pathai S, Lawn SD, Gilbert CE, et al. Accelerated biological ageing in HIV-infected individuals in South Africa. AIDS 2013; 27(15): 2375-84.
[http://dx.doi.org/10.1097/QAD.0b013e328363bf7f] [PMID: 23751258]
[25]
Ambrosioni J, Blanco JL, Reyes-Urueña JM, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV 2021; 8(5): e294-305.
[http://dx.doi.org/10.1016/S2352-3018(21)00070-9] [PMID: 33915101]
[26]
Richman DD. Normal physiology and HIV pathophysiology of human T-cell dynamics. J Clin Invest 2000; 105(5): 565-6.
[http://dx.doi.org/10.1172/JCI9478] [PMID: 10712427]
[27]
Wang Y, Lifshitz L, Gellatly K, et al. HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. Nat Immunol 2020; 21(3): 274-86.
[http://dx.doi.org/10.1038/s41590-020-0593-9] [PMID: 32066947]
[28]
Karaosmanoglu HK. How does the Covıd-19 pandemıc affect the target 90-90-90? Curr HIV Res 2021; 19(2): 103-5.
[http://dx.doi.org/10.2174/1570162XMTExbODUl1] [PMID: 33243126]
[29]
UNAIDS. 2020. Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2020/september/20200921_90-90-90 (Accessed on: 2022 Dec 22).
[30]
Guaraldi G, Borghi V, Milic J, et al. The impact of COVID-19 on UNAIDS 90–90–90 Targets: Calls for new HIV care models. Open Forum Infect Dis 2021; 8(7): ofab283.
[http://dx.doi.org/10.1093/ofid/ofab283] [PMID: 34307725]
[31]
UNAIDS. The Global HIV and AIDS Epidemic. 2022. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics (Accessed on: 2022 Dec 22).
[32]
Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: A multicentre research network study. AIDS 2020; 34(13): F3-8.
[http://dx.doi.org/10.1097/QAD.0000000000002666] [PMID: 32796217]
[33]
Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr 2020; 85(1): 6-10.
[http://dx.doi.org/10.1097/QAI.0000000000002423] [PMID: 32568770]
[34]
Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of Coronavirus Disease 2019 (COVID-19) related hospitalization among people with Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A prospective observational study. Clin Infect Dis 2021; 73(7): e2095-106.
[http://dx.doi.org/10.1093/cid/ciaa1605] [PMID: 33095853]
[35]
Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: A systematic review and meta-analysis. AIDS Res Ther 2022; 19(1): 3.
[http://dx.doi.org/10.1186/s12981-021-00427-y] [PMID: 35031068]
[36]
Bertagnolio S, Thwin SS, Silva R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV 2022; 9(7): e486-95.
[http://dx.doi.org/10.1016/S2352-3018(22)00097-2] [PMID: 35561704]
[37]
Tesoriero JM, Swain CAE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open 2021; 4(2): e2037069.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.37069] [PMID: 33533933]
[38]
Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS 2021; 35(4): F1-F10.
[http://dx.doi.org/10.1097/QAD.0000000000002836] [PMID: 33587448]
[39]
Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis 2020.
[http://dx.doi.org/10.1093/cid/ciaa1198]
[40]
Childs K, Post FA, Norcross C, et al. Hospitalized patients with COVID-19 and human immunodeficiency virus: A case series. Clin Infect Dis 2020; 71(8): 2021-2.
[http://dx.doi.org/10.1093/cid/ciaa657] [PMID: 32459833]
[41]
Jassat W, Cohen C, Tempia S, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: A cohort study. Lancet HIV 2021; 8(9): e554-67.
[http://dx.doi.org/10.1016/S2352-3018(21)00151-X] [PMID: 34363789]
[42]
Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort. Lancet HIV 2020; 7(8): e554-64.
[http://dx.doi.org/10.1016/S2352-3018(20)30164-8] [PMID: 32473657]
[43]
del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med 2021; 174(4): 581-2.
[http://dx.doi.org/10.7326/L20-1399] [PMID: 33872541]
[44]
Ho H, Peluso MJ, Margus C, et al. Clinical outcomes and immunologic characteristics of Coronavirus Disease 2019 in people with human immunodeficiency virus. J Infect Dis 2021; 223(3): 403-8.
[http://dx.doi.org/10.1093/infdis/jiaa380] [PMID: 32601704]
[45]
Pokrovsky VI, Yurin OG. Clinical classification of HIV. Epidemiology and Infectious Diseases 2001; (1): 7-10.
[46]
Etienne N, Karmochkine M, Slama L, et al. HIV infection and COVID-19: Risk factors for severe disease. AIDS 2020; 34(12): 1771-4.
[http://dx.doi.org/10.1097/QAD.0000000000002651] [PMID: 32773476]
[47]
Inciarte A, Gonzalez-Cordon A, Rojas J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: A single-center, prospective observational study. AIDS 2020; 34(12): 1775-80.
[http://dx.doi.org/10.1097/QAD.0000000000002643] [PMID: 32773471]
[48]
Huang J, Xie N, Hu X, et al. Epidemiological, virological and serological features of Coronavirus Disease 2019 (COVID-19) cases in people living with human immunodeficiency virus in Wuhan: A population-based cohort study. Clin Infect Dis 2021; 73(7): e2086-94.
[http://dx.doi.org/10.1093/cid/ciaa1186] [PMID: 32803216]
[49]
Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and people living with human immunodeficiency virus: Outcomes for hospitalized patients in New York City. Clin Infect Dis 2020; 71(11): 2933-8.
[http://dx.doi.org/10.1093/cid/ciaa880] [PMID: 32594164]
[50]
Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 among people living with HIV: A systematic review. AIDS Behav 2021; 25(1): 85-92.
[http://dx.doi.org/10.1007/s10461-020-02983-2] [PMID: 32734438]
[51]
Di Biagio A, Ricci E, Calza L, et al. Factors associated with hospital admission for COVID-19 in HIV patients. AIDS 2020; 34(13): 1983-5.
[http://dx.doi.org/10.1097/QAD.0000000000002663] [PMID: 32796214]
[52]
Kouanfack OSD, Kouanfack C, Billong SC, et al. Epidemiology of opportunistic infections in HIV infected patients on treatment in accredited HIV treatment centers in cameroon. Int J MCH AIDS 2019; 8(2): 163-72.
[http://dx.doi.org/10.21106/ijma.302] [PMID: 32257607]
[53]
Cillóniz C, Dominedò C, Álvarez-Martínez MJ, et al. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. Expert Rev Anti Infect Ther 2019; 17(10): 787-801.
[http://dx.doi.org/10.1080/14787210.2019.1671823] [PMID: 31550942]
[54]
Kaplan JE, Hanson DL, Jones JL, Dworkin MS. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001; 15(14): 1831-6.
[http://dx.doi.org/10.1097/00002030-200109280-00012] [PMID: 11579245]
[55]
Akiyama H, Gummuluru S. HIV-1 persistence and chronic induction of innate immune responses in macrophages. Viruses 2020; 12(7): 711.
[http://dx.doi.org/10.3390/v12070711] [PMID: 32630058]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy